That's kind of why we got excited about this is you've got a compound that's got a known performance effect. Well-studied Sanford Burnham Prebys published a number of great clinical papers on its ability to activate HNF4α but yet why has the industry lagged in turning this into a clinical candidate? Or turning this into an ingredient of choice for the industry? And the heart of that problem lies in it's only available in vanishingly small amounts in nature so it doesn't present itself as a compound to be to be farmed or a compound to be sourced. You have to produce it - but it was difficult to produce. Until now. That's amazing!